HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation

Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities

(2023) Kathleen M. Tornatore et al.   CTS-Clinical and Translational Science

Tacrolimus Pharmacokinetics are Influenced by CYP3A5, Age, and Concomitant Fluconazole in Pediatric Kidney Transplant Patients

(2023) Alaa Alghamdi et al.   CTS-Clinical and Translational Science

Leptin receptor gene polymorphisms in kidney transplant patients with post-transplant diabetes mellitus treated with tacrolimus

(2023) Violetta Dziedziejko et al.   International Immunopharmacology

Lipid Profile Is Negatively Associated with Uremic Toxins in Patients with Kidney Failure—A Tri-National Cohort

(2022) Sam Hobson et al.   Toxins

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

(2022) Fang Cheng et al.   Journal of Immunology Research

Clinical Experience with Extended-Release Tacrolimus in Older Adult Kidney Transplant Recipients: A Retrospective Cohort Study

(2021) Spenser E. January et al.   DRUGS & AGING

Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post–Renal Transplant

(2019) Calvin J. Meaney et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: A single-center experience

(2018) Fahad Aziz et al.   CLINICAL NEPHROLOGY

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype

(2016) N. Pallet et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study

(2016) J.A. García-Bello et al.   TRANSPLANTATION PROCEEDINGS

Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy

(2016) Qi-Jun Wan et al.   Experimental and Therapeutic Medicine

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing

(2015) KA Birdwell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

(2014) Elisabet Størset et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China

(2012) Xiang-guang Meng et al.   ACTA PHARMACOLOGICA SINICA

The Impact of Medicare's Lifetime Immunosuppression Coverage on Racial Disparities in Kidney Graft Survival

(2012) T. F. Page et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients

(2011) Violette Gijsen et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients

(2009) Rogier R Press et al.   THERAPEUTIC DRUG MONITORING

Pharmacokinetics and Immunodynamics of Basiliximab in Pediatric Renal Transplant Recipients on Mycophenolate Mofetil Comedication

(2008) Britta Höcker et al.   TRANSPLANTATION